Published Manuscripts (2019)

Viljoen A, Hoxer CS, Johansen P, Malkin S, Hunt B, Bain SC. Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK. Diabetes, Obesity and Metabolism 2019; 21(3): 611-621.

Malkin S, Russel-Szymczyk M, Liidemann G, Volke V, Hunt B. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. Diabetes Therapy 2019; 10(1): 159-176.

Petitjean A, Smith-Palmer J, Valentine W, Tehard B, Roze S. Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France. BMC Cancer 2019; 19(1): 140.

Roze S, Smith-Palmer J, de Portu S, Delbaere A, de Brouwer B, de Valk HW. Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands. Clinicoeconomics and Outcomes Research 2019; 11: 73-82.

Jendle J, Pöhlmann J, de Portu S, Smith-Palmer J, Roze S. Cost-effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. Diabetes Technology and Therapeutics 2019; 21(3): 110-118.

Billings LK, Mocarski M, Basse A, Hunt B, Valentine WJ, Jodar E. Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA. Clinicoeconomics and Outcomes Research 2019; 11: 271-282.

Smith-Palmer J, Takizawa C, Valentine W. Literature review of the burden of prostate cancer in Germany, France, the United Kingdom and Canada. BMC Urol 2019; 19(1): 19.

Johansen P, Hunt B, Iyer NN, Dang-Tan T, Pollock RF. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. Advances in Therapy 2019; 36(5): 1190-1199.

Roze S, Smith-Palmer J, Delbaere A, Bjornstrom K, de Portu S, Valentine W, Honkasalo M. Cost-Effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Patients with Poorly Controlled Type 2 Diabetes in Finland. Diabetes Therapy 2019; 10(2): 563-574.

Pöhlmann J, Russel-Szymczyk M, Holík P, Rychna K, Hunt B. Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi. Diabetes Therapy 2019; 10(2): 493-508.

Mezquita Raya P, Ampudia Blasco FJ, Hunt B, Martin V, Thorsted BL, Basse A, Price H. Evaluating the long-term cost-effectiveness of IDegLira for type 2 diabetes in Spain based on real-world clinical evidence. Diabetes, Obesity and Metabolism 2019; 21: 1349–1356.

Gæde P, Johansen P, Tikkanen CK, Pollock RF, Hunt B, Malkin SJP. Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. Diabetes Therapy 2019; 10(4): 1297-1317.

Malkin SJP, Russel-Szymczyk M, Psota M, Hlavinkova L, Hunt B. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. Advances in Therapy 2019; 36(8): 2034-2051.

Close phone HUD
+41 61 271 6214
Dial with SkypeOutDial with SkypeOut
Close phone HUD
+41 79 340 4644
Dial with SkypeOutDial with SkypeOut